TCR player Immatics combines with Perceptive’s blank check operator, scooping $252M and gaining a listing on Nasdaq
Perceptive Advisors’ blank check company has inked a deal — and it’s landing right in the middle of a global pandemic that’s roiling the industry.
Their Arya Sciences venture, which completed an IPO in the fall of 2018, will now combine with TCR player Immatics — a biotech with roots in Germany and Houston. That gives Immatics $148 million sitting in Arya’s coffers plus $104 million in added funding from a group of investors led by Perceptive.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.